Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant

使用先天免疫兴奋剂 PUL-042 扩大清髓性癌症治疗的市场和成功率

• 批准号: 8875976
• 负责人: Brenton Scott
• 金额: $ 98.25万
• 依托单位: PULMOTECT, INC
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-02-01 至 2018-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8875976
• 关键词: Achievement; Address; Agonist; Agreement; Aspergillus fumigatus; Asthma; Bacteria; Basic Science; Biotechnology; Breathing; Cancer Patient; Clinical; Clinical Research; Clinical Trials; Collaborations; Communicable Diseases; Cyclic GMP; Data; Development; Dose; Double-blind trial; Enrollment; Epithelium; Evaluation; Funding; Goals; Health; Hematologic Neoplasms; Hematology; Human; Immune; Immune system; Immunity; Immunocompromised Host; Incidence; Individual; Infection; Lead; Lower Respiratory Tract Infection; Lung; Marketing; Methods; Mus; Myeloablative Chemotherapy; Nasal Lavage Fluid; Parainfluenza; Patients; Pharmaceutical Preparations; Phase; Phase II Clinical Trials; Placebos; Pneumonia; Population Study; Positioning Attribute; Prevention; Process; Pulmonology; Randomized; Recruitment Activity; Research; Resistance; Safety; Secure; Seeds; Sendai virus; Severities; Site; Solutions; Staging; Survival Rate; TLR2 gene; Technology; Testing; Therapeutic; Time; Toll-like receptors; Translating; United States National Institutes of Health; University of Texas M D Anderson Cancer Center; Vaccines; Viral; Virus; Virus Diseases; aerosolized; base; cancer therapy; clinical research site; design; disease transmission; follow-up; fungus; healthy volunteer; immune resistance; immunosuppressed; influenzavirus; man; microbial; microbiome; neutralizing antibody; novel therapeutics; oncology; outreach; pandemic influenza; pathogen; phase I trial; phase II trial; prevent; resistance mechanism; respiratory; response; success; technology development; virome

 DESCRIPTION (provided by applicant):

 描述（由申请人提供）：